RESUMO
This Medical News article discusses how cardiac xenotransplantation with genetically modified pig hearts might help relieve the shortage of human donor hearts.
Assuntos
Transplante de Coração , Transplante Heterólogo , Animais , Humanos , Animais Geneticamente Modificados , Sobrevivência de Enxerto , Transplante de Coração/tendências , Suínos , Transplante Heterólogo/tendências , PrevisõesAssuntos
Xenoenxertos , Transplante de Órgãos , Suínos , Obtenção de Tecidos e Órgãos , Transplante Heterólogo , Animais , Humanos , Transplante de Órgãos/ética , Transplante de Órgãos/métodos , Transplante de Órgãos/tendências , Obtenção de Tecidos e Órgãos/ética , Obtenção de Tecidos e Órgãos/métodos , Obtenção de Tecidos e Órgãos/tendências , Xenoenxertos/transplante , Transplante Heterólogo/ética , Transplante Heterólogo/métodos , Transplante Heterólogo/tendênciasAssuntos
Bioengenharia/tendências , Previsões , Engenharia Genética/tendências , Transplante de Órgãos/tendências , Engenharia Tecidual/métodos , Transplante de Tecidos/tendências , Imunologia de Transplantes , Animais , Engenharia Genética/métodos , Genoma , Humanos , Engenharia Tecidual/tendências , Transplante Heterólogo/tendênciasRESUMO
PURPOSE: Liver transplantation is the most important achievement in the twentieth and twenty-first century. It is the gold standard treatment for hepatocellular carcinoma. However, it provides the best results when performed under strict selection criteria. Nevertheless, organ supply is overwhelmed by the number of patients on the waiting list. There are certain strategies to expand the donor pool such as split liver transplantation, use of extended criteria donors, and living donor liver transplantation. Xenotransplantation can also be a strategy in decreasing the organ shortage. We reviewed the current status of xenotransplantation. METHODS: We evaluated the historical attempts of xenotransplantation to humans and also made a summary of the preclinical studies in the field. RESULTS: Molecular biology and genetic engineering are developing with an incredible speed. There are great achievements made in cell therapy, 3D bioprinting of the organs, and ultimately xenotransplantation. There is a vast amount of problems to be handled before evaluating the efficacy of xenotransplantation in the treatment of hepatocellular carcinoma. Major problems include antibody-mediated rejection to antigens such as galactose âº1-3 galactose, N- glycolylneuraminic acid, ß1,4-N-acetylgalactosaminyltransferase, lethal thrombocytopenia, and erythrocyte sequestration. Antibody mediated rejection to these specific antigens are addressed using gene editing technology including CRISPR Cas9, TALEN and other recombination methods. Although hyperacute rejection is reduced, long-term survival could not be achieved in experimental models. CONCLUSION: The future is yet to come, there are developments made in the field of genetic editing, immunosuppressive medication, and pretransplant desensitization techniques. Therefore, we believe that xenotransplantation will be in clinical practice, at least for treatment of critically ill patients.
Assuntos
Carcinoma Hepatocelular/cirurgia , Rejeição de Enxerto/imunologia , Neoplasias Hepáticas/cirurgia , Transplante de Fígado/métodos , Transplante Heterólogo/métodos , Aloenxertos/imunologia , Aloenxertos/provisão & distribuição , Animais , Carcinoma Hepatocelular/mortalidade , Engenharia Genética/métodos , Rejeição de Enxerto/prevenção & controle , Humanos , Fígado/imunologia , Neoplasias Hepáticas/mortalidade , Transplante de Fígado/efeitos adversos , Transplante de Fígado/tendências , Especificidade da Espécie , Fatores de Tempo , Transplante Heterólogo/efeitos adversos , Transplante Heterólogo/tendênciasRESUMO
Lack of an appropriate animal model to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for COVID-19 pandemic disease, represents a significant hurdle in the process of understanding disease biology and evaluating therapeutic and preventive candidates. It is time for public health agencies to revisit regulation on transplantation of human pluripotent stem cells for the possibility of the development of a humanized mice model with a humanized lung.
Assuntos
Infecções por Coronavirus/patologia , Modelos Animais de Doenças , Células-Tronco Pluripotentes/transplante , Pneumonia Viral/patologia , Infecções Respiratórias/patologia , Transplante Heterólogo/legislação & jurisprudência , Animais , COVID-19 , Humanos , Camundongos , Pandemias , Pesquisa/legislação & jurisprudência , Pesquisa/normas , Pesquisa/tendências , Transplante Heterólogo/tendênciasAssuntos
Betacoronavirus/fisiologia , Coronaviridae/fisiologia , Infecções por Coronavirus/epidemiologia , Pandemias , Pneumonia Viral/epidemiologia , Suínos/virologia , Transplante Heterólogo , Animais , Animais Geneticamente Modificados , Biomarcadores , Bioprótese , Coagulação Sanguínea/fisiologia , COVID-19 , Ensaios Clínicos como Assunto , Infecções por Coronavirus/prevenção & controle , Infecções por Coronavirus/transmissão , Receptor de Proteína C Endotelial/fisiologia , Comitês de Ética em Pesquisa , Sobrevivência de Enxerto , Próteses Valvulares Cardíacas , Xenoenxertos , Especificidade de Hospedeiro , Humanos , Transplante das Ilhotas Pancreáticas , Fígado , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Pneumonia Viral/transmissão , Proteína C/fisiologia , Valva Pulmonar/cirurgia , Valva Pulmonar/transplante , SARS-CoV-2 , Subpopulações de Linfócitos T/imunologia , Transplante Heterólogo/efeitos adversos , Transplante Heterólogo/tendênciasRESUMO
Currently, type 1 diabetes requires lifelong insulin injection and careful blood glucose control to prevent secondary complications, but islet transplantation could make a type 1 diabetic patient insulin independent. On the other hand, islet transplantation needs human donors and donor shortage is the most serious issue. To alleviate the donor shortage, non-heart-beating and living donors were used; in addition, the efficacy of islet isolation and transplantation has been improved. However, the donor shortage issue will not be solved as long as human donors are the only source. To solve the donor shortage issue, islet xenotransplantation using porcine islets was initiated in 1994. Islet xenotransplantation has a potential to cure many type 1 diabetic patients, although there is the risk of developing serious or novel infection. Therefore, the World Health Organization has been interested in xenotransplantation, and the International Xenotransplantation Association (IXA) has published consensus statements to initiate xenogeneic islet transplantation. Clinical islet xenotransplantation was conducted under the official regulation, and safety and efficacy data have been accumulated. Currently an efficient method to overcome xenorejection is an important research target. In addition to traditional immunosuppressive drugs and immune isolation methods, the gene modification with CRISPR and blastocyst complementation have been investigated with promising outcomes. Once the xenorejection issue is overcome, islet xenotransplantation should become a curative treatment for type 1 diabetic patients.
Assuntos
Diabetes Mellitus Tipo 1/cirurgia , Transplante das Ilhotas Pancreáticas/tendências , Transplante Heterólogo/tendências , Animais , Humanos , Doadores de Tecidos , Transplante HomólogoRESUMO
There is a well-known worldwide shortage of deceased human donor organs for clinical transplantation. The transplantation of organs from genetically engineered pigs may prove an alternative solution. In the past 5 years, there have been sequential advances that have significantly increased pig graft survival in nonhuman primates. This progress has been associated with (1) the availability of increasingly sophisticated genetically engineered pigs; (2) the introduction of novel immunosuppressive agents, particularly those that block the second T-cell signal (costimulation blockade); (3) a better understanding of the inflammatory response to pig xenografts; and (4) increasing experience in the management of nonhuman primates with pig organ or cell grafts. The range of investigations required in experimental studies has increased. The standard immunologic assays are still carried out, but increasingly investigations aimed toward other pathobiologic barriers (e.g., coagulation dysregulation and inflammation) have become more important in determining injury to the graft.Now that prolonged graft survival, extending to months or even years, is increasingly being obtained, the function of the grafts can be more reliably assessed. If the source pigs are bred and housed under biosecure isolation conditions, and weaned early from the sow, most microorganisms can be eradicated from the herd. The potential risk of porcine endogenous retrovirus (PERV) infection remains unknown, but is probably small. Attention is being directed toward the selection of patients for the first clinical trials of xenotransplantation.
Assuntos
Pesquisa/tendências , Transplante Heterólogo/métodos , Transplante Heterólogo/tendências , Imunidade Adaptativa , Animais , Animais Geneticamente Modificados , Ensaios Clínicos como Assunto , Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto/imunologia , Xenoenxertos/imunologia , Xenoenxertos/metabolismo , História do Século XX , História do Século XXI , Humanos , Imunização , Inflamação/etiologia , Inflamação/metabolismo , Inflamação/patologia , Pesquisa/história , Imunologia de Transplantes , Transplante Heterólogo/efeitos adversos , Transplante Heterólogo/normas , Resultado do TratamentoRESUMO
Study of lung xenografts has proven useful to understand the remaining barriers to successful transplantation of other organ xenografts. In this chapter, the history and current status of lung xenotransplantation will be briefly reviewed, and two different experimental models, the ex vivo porcine-to-human lung perfusion and the in vivo xenogeneic lung transplantation, will be presented. We will focus on the technical details of these lung xenograft models in sufficient detail, list the needed materials, and mention analysis techniques to allow others to adopt them with minimal learning curve.
Assuntos
Xenoenxertos , Transplante de Pulmão/métodos , Modelos Animais , Transplante Heterólogo/métodos , Animais , Biomarcadores , Catéteres , Citocinas/metabolismo , Sobrevivência de Enxerto , Hemodinâmica , Humanos , Transplante de Pulmão/efeitos adversos , Transplante de Pulmão/tendências , Papio , Perfusão , Radiografia Torácica , Testes de Função Respiratória , Suínos , Transplante Heterólogo/efeitos adversos , Transplante Heterólogo/tendênciasRESUMO
Xenotransplantation, or the grafting of organs from one species to another, may seem at first a far cry from brain death, but there is rising hope in some quarters of the biomedical community that such transplants may reduce, even obviate, the need to harvest human organs-and hence eliminate the primary reason for needing an unambiguous definition of brain death. As with all research on the frontiers of biomedicine, xenotransplantation raises its own ethical quandaries. One concern that has long occupied ethical thought is the degree to which advances in science and technology should control the boundaries between the human and the nonhuman. Might the dimming of a previously entrenched bright line between species entail negative consequences for concepts, such as human dignity and bodily integrity, that historically anchored the protection of both human and animal subjects in biomedical treatment and research? To date, ethical thinking about xenotransplantation, and about gene editing, has largely been left in the hands of scientists, subject only to loose supervision by institutional review boards and animal welfare committees whose remit may be too narrow to address age-old moral concerns.
Assuntos
Experimentação Animal/ética , Direitos dos Animais/normas , Bem-Estar do Animal , Transplante Heterólogo , Animais , Pesquisa Biomédica/ética , Pesquisa Biomédica/tendências , Humanos , Invenções/ética , Invenções/tendências , Princípios Morais , Transplante Heterólogo/ética , Transplante Heterólogo/métodos , Transplante Heterólogo/tendênciasRESUMO
Xenotransplantation is an attractive solution to the problem of allograft shortage. However, transplants across discordant species barriers are subject to vigorous immunologic and pathobiologic hurdles, some of which might be overcome with the induction of immunologic tolerance. Several strategies have been designed to induce tolerance to a xenograft at both the central (including induction of mixed chimerism and thymic transplantation) and peripheral (including adoptive transfer of regulatory cells and blocking T cell costimulation) levels. Currently, xenograft tolerance has been well-established in rodent models, but these protocols have not yet achieved similar success in nonhuman primates. This review will discuss the major barriers that impede the establishment of immunological tolerance across xenogeneic barriers and the potential solution to these challenges, and provide a perspective on the future of the development of novel tolerance-inducing strategies.
Assuntos
Sobrevivência de Enxerto/imunologia , Xenoenxertos/fisiologia , Tolerância ao Transplante , Transplante Heterólogo , Animais , Xenoenxertos/imunologia , Humanos , Tolerância Imunológica , Linfócitos T/imunologia , Timo/imunologia , Timo/transplante , Quimeras de Transplante/imunologia , Transplante Heterólogo/tendênciasRESUMO
Objective: To summarize the research progress on the source and selection of donor cells in the field of islet replacement therapy for diabetes mellitus. Methods: Domestic and abroad literature concerning islet replacement therapy for diabetes mellitus, as well as donor source and donor selection was reviewed and analyzed thoroughly. Results: The shortage of donor supply is still a major obstacle for the widely clinical application of pancreatic islet transplantation (PIT). Currently, in addition to the progress on the allogeneic/autologous donor islet supply, some remarkable achievements have been also attained in the application of xenogeneic islet (from pig donor), as well as islet like cells derived from stem cells and islet cell line, potentially enlarging the source of implantable cells. Conclusion: Adequate and suitable donor cell supply is an essential prerequisite for widely clinical application of PIT therapy for type 1 diabetes mellitus (T1DM). Further perfection of organ donation system, together with development of immune-tolerance induction, gene and bioengineering technology etc. will possibly solve the problem of donor cell shortage and provide a basis for clinical application of cellular replacement therapy for T1DM.
Assuntos
Diabetes Mellitus Tipo 1/cirurgia , Transplante das Ilhotas Pancreáticas/métodos , Transplante das Ilhotas Pancreáticas/tendências , Animais , Diabetes Mellitus Tipo 1/imunologia , Tolerância Imunológica , Ilhotas Pancreáticas , Transplante das Ilhotas Pancreáticas/imunologia , Pesquisa/tendências , Transplante de Células-Tronco/tendências , Suínos , Transplante Heterólogo/tendênciasRESUMO
Among the innovations for the treatment of type 1 diabetes, islet transplantation is a less invasive method of treatment, although it is still in development. One of the greatest barriers to this technique is the low number of pancreas donors and the low number of pancreases that are available for transplantation. Rodent models have been chosen in most studies of islet rejection and type 1 diabetes prevention to evaluate the quality and function of isolated human islets and to identify alternative solutions to the problem of islet scarcity. The purpose of this study is to conduct a review of islet xenotransplantation experiments from humans to rodents, to organize and analyze the parameters of these experiments, to describe trends in experimental modeling and to assess the viability of this procedure. In this study, we reviewed recently published research regarding islet xenotransplantation from humans to rodents, and we summarized the findings and organized the relevant data. The included studies were recent reports that involved xenotransplantation using human islets in a rodent model. We excluded the studies that related to isotransplantation, autotransplantation and allotransplantation. A total of 34 studies that related to xenotransplantation were selected for review based on their relevance and current data. Advances in the use of different graft sites may overcome autoimmunity and rejection after transplantation, which may solve the problem of the scarcity of islet donors in patients with type 1 diabetes.
Assuntos
Diabetes Mellitus Experimental/cirurgia , Transplante das Ilhotas Pancreáticas/métodos , Modelos Animais , Transplante Heterólogo/métodos , Animais , Sobrevivência de Enxerto , Humanos , Transplante das Ilhotas Pancreáticas/estatística & dados numéricos , Transplante das Ilhotas Pancreáticas/tendências , Camundongos Endogâmicos C57BL/cirurgia , Roedores , Transplante Heterólogo/estatística & dados numéricos , Transplante Heterólogo/tendênciasRESUMO
Among the innovations for the treatment of type 1 diabetes, islet transplantation is a less invasive method of treatment, although it is still in development. One of the greatest barriers to this technique is the low number of pancreas donors and the low number of pancreases that are available for transplantation. Rodent models have been chosen in most studies of islet rejection and type 1 diabetes prevention to evaluate the quality and function of isolated human islets and to identify alternative solutions to the problem of islet scarcity. The purpose of this study is to conduct a review of islet xenotransplantation experiments from humans to rodents, to organize and analyze the parameters of these experiments, to describe trends in experimental modeling and to assess the viability of this procedure. In this study, we reviewed recently published research regarding islet xenotransplantation from humans to rodents, and we summarized the findings and organized the relevant data. The included studies were recent reports that involved xenotransplantation using human islets in a rodent model. We excluded the studies that related to isotransplantation, autotransplantation and allotransplantation. A total of 34 studies that related to xenotransplantation were selected for review based on their relevance and current data. Advances in the use of different graft sites may overcome autoimmunity and rejection after transplantation, which may solve the problem of the scarcity of islet donors in patients with type 1 diabetes.